The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study
Open accessAbstract
OBJECTIVE: To characterise whether some selective serotonin reuptake inhibitor (SSRI) antidepressants reduce tamoxifen's effectiveness by inhibiting its bioactivation by cytochrome P450 2D6 (CYP2D6). DESIGN: Population based cohort study. PARTICIPANTS: Women living in Ontario aged 66 years or older treated with tamoxifen for breast cancer between 1993 and 2005 who had overlapping treatment with a single SSRI. MAIN OUTCOME MEASURES: Risk of death from breast cancer after completion of tamoxifen treatment, as a function of the proportion of time on tamoxifen during which each SSRI had been co-prescribed. RESULTS: Of 2430 women treated with tamoxifen and a single SSRI, 374 (15.4%) died of breast cancer during follow-up (mean follow-up 2.38 years, SD 2.59). After adjustment for age, duration of tamoxifen treatment, and other potential confounders, absolute increases of 25%, 50%, and 75% in the proportion of time on tamoxifen with overlapping use of paroxetine (an irreversible inhibitor of CYP2D6) were associated with 24%, 54%, and 91% increases in the risk of death from breast cancer, respectively (P<0.05 for each comparison). By contrast, no such risk was seen with other antidepressants. We estimate that use of paroxetine for 41% of tamoxifen treatment (the median overlap in our sample) would result in one additional breast cancer death within five years of cessation of tamoxifen for every 19.7 (95% confidence interval 12.5 to 46.3) patients so treated; the risk with more extensive overlap would be greater. CONCLUSION: Paroxetine use during tamoxifen treatment is associated with an increased risk of death from breast cancer, supporting the hypothesis that paroxetine can reduce or abolish the benefit of tamoxifen in women with breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Partial residuals for the proportional hazards regression model
SCHOENFELD, D. (1982) · Biometrika · doi:10.1093/biomet/69.1.239 · Cited by 3,111
Pharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939
Loprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., LaVasseur, B. I., Barton, D. L., Novotny, P. J., Dakhil, S. R., Rodger, K., Rummans, T. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03403-6 · Cited by 737
Major depression after breast cancer: a review of epidemiology and treatment
Fann, J. R., Thomas-Rich, A. M., Katon, W. J., Cowley, D., Pepping, M., McGregor, B. A., & Gralow, J. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2007.10.008 · Cited by 586
Outpatient gatifloxacin therapy and dysglycemia in older adults.
Park-Wyllie, L. Y., Juurlink, D. N., Kopp, A., Shah, B. R., Stukel, T. A., Stumpo, C., Dresser, L., Low, D. E., & Mamdani, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055191 · Cited by 367
Self-citationCoyne, J. C., Palmer, S. C., Shapiro, P. J., Thompson, R., & DeMichele, A. (2004) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2003.08.012 · Cited by 123
Cited by
2016 IMS Recommendations on women’s midlife health and menopause hormone therapy
Baber, R. J., Panay, N., & Fenton, A. (2016) · Climacteric · doi:10.3109/13697137.2015.1129166 · Cited by 964
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Rowland, M., Peck, C., & Tucker, G. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100540 · Cited by 662
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Drug combination therapy increases successful drug repositioning
Sun, W., Sanderson, P. E., & Zheng, W. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.05.015 · Cited by 436
Addressing phenoconversion: the Achilles' heel of personalized medicine
Shah, R. R., & Smith, R. L. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12441 · Cited by 278
Metadata
- Authors
- Kelly, C. M., Juurlink, D. N., Gomes, T., Duong-Hua, M., Pritchard, K. I., Austin, P. C., & Paszat, L. F.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2010-02-08
- Volume
- 340
- Issue
- feb08 1
- Pages
- c693-c693
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W1997530992
- Cited by
- 466
- References
- 6
- FWCI
- 61.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. https://app.cochat.ai/papers/10.1136/bmj.c693
- The paper
- Kelly, C. M., Juurlink, D. N., Gomes, T., Duong-Hua, M., Pritchard, K. I., Austin, P. C., & Paszat, L. F. (2010). Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. https://doi.org/10.1136/bmj.c693
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.